| Unknown | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Resid NCT04197687 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Patho NCT03872388 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence NCT04054557 | Thomas Jefferson University | N/A |
| Completed | SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer NCT03411070 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors NCT03407716 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery NCT03317405 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and N NCT03094052 | University of California, San Francisco | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treatin NCT03101748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positi NCT03281902 | Mayo Clinic | — |
| Completed | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast NCT03106415 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Tr NCT03012100 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer NCT02912312 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC NCT02593175 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Tr NCT02689427 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment NCT02754752 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer NCT02474173 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer NCT02276443 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estro NCT02311933 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients NCT02003209 | National Cancer Institute (NCI) | Phase 3 |
| Suspended | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage III NCT02037529 | Academic and Community Cancer Research United | Phase 3 |
| Active Not Recruiting | The Role of Lifestyle Factors in Breast Cancer-Related Outcomes NCT02079662 | M.D. Anderson Cancer Center | N/A |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer NCT01463072 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer NCT01349959 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT01351909 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive NCT01327781 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer NCT01275677 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01251874 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Rec NCT01142401 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Ca NCT00770809 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated NCT00684983 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cance NCT00390455 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT00376688 | National Cancer Institute (NCI) | Phase 2 |